The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice
Open accessAbstract
Human leukemic stem cells, like other cancer stem cells, are hypothesized to be rare, capable of incomplete differentiation, and restricted to a phenotype associated with early hematopoietic progenitors or stem cells. However, recent work in other types of tumors has challenged the cancer stem cell model. Using a robust model of xenotransplantation based on NOD/SCID/IL2Rγc-deficient mice, we confirmed that human leukemic stem cells, functionally defined by us as SCID leukemia-initiating cells (SL-ICs), are rare in acute myelogenous leukemia (AML). In contrast to previous results, SL-ICs were found among cells expressing lineage markers (i.e., among Lin+ cells), CD38, or CD45RA, all markers associated with normal committed progenitors. Remarkably, each engrafting fraction consistently recapitulated the original phenotypic diversity of the primary AML specimen and contained self-renewing leukemic stem cells, as demonstrated by secondary transplants. While SL-ICs were enriched in the Lin-CD38- fraction compared with the other fractions analyzed, SL-ICs in this fraction represented only one-third of all SL-ICs present in the unfractionated specimen. These results indicate that human AML stem cells are rare and enriched but not restricted to the phenotype associated with normal primitive hematopoietic cells. These results suggest a plasticity of the cancer stem cell phenotype that we believe has not been previously described.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Bonnet, D., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 5,864
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783 · cited 1×
“As noted, the original work on AML stem cells focused on the CD34+CD38– fractions of cells (19).”
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice
O’Brien, C. A., Pollett, A., Gallinger, S., & Dick, J. E. (2007) · Nature · doi:10.1038/nature05372 · Cited by 4,087
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Efficient tumour formation by single human melanoma cells
Quintana, E., Shackleton, M., Sabel, M. S., Fullen, D. R., Johnson, T. M., & Morrison, S. J. (2008) · Nature · doi:10.1038/nature07567 · Cited by 1,796
Shultz, L. D., Lyons, B. L., Burzenski, L. M., Gott, B., Chen, X., Chaleff, S., Kotb, M., Gillies, S. D., King, M., Mangada, J., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.6477 · Cited by 1,728
Multiple defects in innate and adaptive immunologic function in NOD/LtSz- scid mice.
Shultz, L. D., Schweitzer, P. A., Christianson, S. W., Gott, B., Schweitzer, I. B., Tennent, B., McKenna, S., Mobraaten, L., Rajan, T. V., Greiner, D. L., et al. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.1.180 · Cited by 1,223
Targeting of CD44 eradicates human acute myeloid leukemic stem cells
Jin, L., Hope, K. J., Zhai, Q., Smadja-Joffe, F., & Dick, J. E. (2006) · Nature Medicine · doi:10.1038/nm1483 · Cited by 1,219
Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice
Ishikawa, F., Yasukawa, M., Lyons, B., Yoshida, S., Miyamoto, T., Yoshimoto, G., Watanabe, T., Akashi, K., Shultz, L. D., & Harada, M. (2005) · Blood · doi:10.1182/blood-2005-02-0516 · Cited by 932
Cited by
Tumour heterogeneity and cancer cell plasticity
Meacham, C. E., & Morrison, S. J. (2013) · Nature · doi:10.1038/nature12624 · Cited by 2,446
Lagadinou, E. D., Sach, A., Callahan, K., Rossi, R. M., Neering, S. J., Minhajuddin, M., Ashton, J. M., Pei, S., Grose, V., O’Dwyer, K. M., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2012.12.013 · Cited by 1,399
Cancer Stem Cells: Current Status and Evolving Complexities
Visvader, J. E., & Lindeman, G. J. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.05.007 · Cited by 1,287
Vu, L. P., Pickering, B. F., Cheng, Y., Zaccara, S., Nguyen, D., Minuesa, G., Chou, T., Chow, A., Saletore, Y., MacKay, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4416 · Cited by 1,237
Self-citationCancer Stem Cells: Impact, Heterogeneity, and Uncertainty
Magee, J. A., Piskounova, E., & Morrison, S. J. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.003 · Cited by 1,101
Stem cell gene expression programs influence clinical outcome in human leukemia
Eppert, K., Takenaka, K., Lechman, E. R., Waldron, L., Nilsson, B., van Galen, P., Metzeler, K. H., Poeppl, A., Ling, V., Beyene, J., et al. (2011) · Nature Medicine · doi:10.1038/nm.2415 · Cited by 1,041
Farge, T., Saland, E., de Toni, F., Aroua, N., Hosseini, M., Perry, R., Bosc, C., Sugita, M., Stuani, L., Fraisse, M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0441 · Cited by 912
Self-citationA 17-gene stemness score for rapid determination of risk in acute leukaemia
Ng, S. W. K., Mitchell, A., Kennedy, J. A., Chen, W. C., McLeod, J., Ibrahimova, N., Arruda, A., Popescu, A., Gupta, V., Schimmer, A. D., et al. (2016) · Nature · doi:10.1038/nature20598 · Cited by 912
Pollyea, D. A., Stevens, B. M., Jones, C. L., Winters, A., Pei, S., Minhajuddin, M., D’Alessandro, A., Culp-Hill, R., Riemondy, K. A., Gillen, A. E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0233-1 · Cited by 778
Yu, Z., Pestell, T. G., Lisanti, M. P., & Pestell, R. G. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.08.022 · Cited by 647
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells
Jones, C. L., Stevens, B. M., D'Alessandro, A., Reisz, J. A., Culp-Hill, R., Nemkov, T., Pei, S., Khan, N., Adane, B., Ye, H., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.005 · Cited by 585
Khwaja, A., Bjorkholm, M., Gale, R. E., Levine, R. L., Jordan, C. T., Ehninger, G., Bloomfield, C. D., Estey, E., Burnett, A., Cornelissen, J. J., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.10 · Cited by 592
Understanding cancer stem cell heterogeneity and plasticity
Tang, D. G. (2012) · Cell Research · doi:10.1038/cr.2012.13 · Cited by 563
Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche
Ye, H., Adane, B., Khan, N., Sullivan, T., Minhajuddin, M., Gasparetto, M., Stevens, B., Pei, S., Balys, M., Ashton, J. M., et al. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.06.001 · Cited by 543
Paris, J., Morgan, M., Campos, J., Spencer, G. J., Shmakova, A., Ivanova, I., Mapperley, C., Lawson, H., Wotherspoon, D. A., Sepulveda, C., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.03.021 · Cited by 502
Biology and relevance of human acute myeloid leukemia stem cells
Thomas, D., & Majeti, R. (2017) · Blood · doi:10.1182/blood-2016-10-696054 · Cited by 500
Moschoi, R., Imbert, V., Nebout, M., Chiche, J., Mary, D., Prebet, T., Saland, E., Castellano, R., Pouyet, L., Collette, Y., et al. (2016) · Blood · doi:10.1182/blood-2015-07-655860 · Cited by 463
Self-citationCell Plasticity and Heterogeneity in Cancer
Marjanovic, N. D., Weinberg, R. A., & Chaffer, C. L. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.184655 · Cited by 400
Functional Heterogeneity of Genetically Defined Subclones in Acute Myeloid Leukemia
Klco, J. M., Spencer, D. H., Miller, C. A., Griffith, M., Lamprecht, T. L., O’Laughlin, M., Fronick, C., Magrini, V., Demeter, R. T., Fulton, R. S., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.031 · Cited by 395
Tirino, V., Desiderio, V., Paino, F., De Rosa, A., Papaccio, F., La Noce, M., Laino, L., De Francesco, F., & Papaccio, G. (2013) · The FASEB Journal · doi:10.1096/fj.12-218222 · Cited by 395
BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation
Raffel, S., Falcone, M., Kneisel, N., Hansson, J., Wang, W., Lutz, C., Bullinger, L., Poschet, G., Nonnenmacher, Y., Barnert, A., et al. (2017) · Nature · doi:10.1038/nature24294 · Cited by 354
Zhang, B., Ho, Y. W., Huang, Q., Maeda, T., Lin, A., Lee, S.-U., Hair, A., Holyoake, T. L., Huettner, C., & Bhatia, R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.018 · Cited by 348
Animal models for bone tissue engineering and modelling disease
McGovern, J. A., Griffin, M., & Hutmacher, D. W. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.033084 · Cited by 304
AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells
Pei, S., Minhajuddin, M., Adane, B., Khan, N., Stevens, B. M., Mack, S. C., Lai, S., Rich, J. N., Inguva, A., Shannon, K. M., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.05.021 · Cited by 301
Therapeutic targeting of acute myeloid leukemia stem cells
Pollyea, D. A., & Jordan, C. T. (2017) · Blood · doi:10.1182/blood-2016-10-696039 · Cited by 299
Grimwade, D., & Freeman, S. D. (2014) · Blood · doi:10.1182/blood-2014-05-577593 · Cited by 262
Shih, A. H., Jiang, Y., Meydan, C., Shank, K., Pandey, S., Barreyro, L., Antony-Debre, I., Viale, A., Socci, N., Sun, Y., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.009 · Cited by 236
“More recent studies have suggested that leukemic stem cell (LSC) activity can also be detected in committed myeloid progenitors (Kirstetter et al., 2008; Sarry et al., 2011).”
BackgroundBarreyro, L., Will, B., Bartholdy, B., Zhou, L., Todorova, T. I., Stanley, R. F., Ben-Neriah, S., Montagna, C., Parekh, S., Pellagatti, A., et al. (2012) · Blood · doi:10.1182/blood-2012-01-404699 · Cited by 201
Selective killing of candidate AML stem cells by antibody targeting of IL1RAP
Askmyr, M., Ågerstam, H., Hansen, N., Gordon, S., Arvanitakis, A., Rissler, M., Juliusson, G., Richter, J., Järås, M., & Fioretos, T. (2013) · Blood · doi:10.1182/blood-2012-09-458935 · Cited by 127
IL1RAP potentiates multiple oncogenic signaling pathways in AML
Mitchell, K., Barreyro, L., Todorova, T. I., Taylor, S. J., Antony-Debré, I., Narayanagari, S.-R., Carvajal, L. A., Leite, J., Piperdi, Z., Pendurti, G., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180147 · Cited by 97
Liquid-based three-dimensional tumor models for cancer research and drug discovery
Ham, S. L., Joshi, R., Thakuri, P. S., & Tavana, H. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216643772 · Cited by 91
Negrotto, S., Ng, K. P., Jankowska, A. M., Bodo, J., Gopalan, B., Guinta, K., Mulloy, J. C., Hsi, E., Maciejewski, J., & Saunthararajah, Y. (2012) · Leukemia · doi:10.1038/leu.2011.207 · Cited by 90
Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera
Tsuruta-Kishino, T., Koya, J., Kataoka, K., Narukawa, K., Sumitomo, Y., Kobayashi, H., Sato, T., & Kurokawa, M. (2017) · Oncogene · doi:10.1038/onc.2016.478 · Cited by 41
Metadata
- Authors
- Sarry, J.-E., Murphy, K., Perry, R., Sanchez, P. V., Secreto, A., Keefer, C., Swider, C. R., Strzelecki, A.-C., Cavelier, C., Récher, C., Mansat-De Mas, V., Delabesse, E., Danet-Desnoyers, G., & Carroll, M.
- Venue
- Journal of Clinical Investigation
- Published
- 2011-01-04
- Volume
- 121
- Issue
- 1
- Pages
- 384-395
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2090757708
- Cited by
- 386
- References
- 30
- FWCI
- 17.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.